NSCLC patients with KRAS mutation had longer PFS than those with wild-type KRAS mutation (mPFS 13.7, 95% CI 6.77–20.6), though no OS benefit was observed. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.